Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus ≥ 3 (p = 0.014), presence of comorbidities (0-1 versus ≥ 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus ≥ 3 (p = 0.001), presence of comorbidities (0-1 versus ≥ 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.

Babak Myeloma Group Department of Pathophysiology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology Faculty of Medicine University Hospital Brno and Masaryk University Jihlavska 20 Brno 625 00 Czech Republic

Zobrazit více v PubMed

Susek KH, Gran Ch, Ljunggren HG, et al. Outcome of COVID-19 in multiple myeloma patients in relation to treatment. Eur J Hematology. 2020;105:751–754. doi: 10.1111/ejh.13502. PubMed DOI PMC

Wu Z, McGoogan JM. Characteristics of and important lessions from the coronarovirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases the Chinese Center for Disease Control and Prevention. JAMA. 2020;312:1239–1242. doi: 10.1001/jama.2020.2648. PubMed DOI

Guan WJ, Ni ZY, Hu Yu, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. PubMed DOI PMC

Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable for SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791. PubMed PMC

Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;72:340–350. doi: 10.1093/cid/ciaa863. PubMed DOI PMC

Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582–1589. doi: 10.1001/jama.2020.4783. PubMed DOI PMC

Grein J, Ohmagan N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382:2327–2336. doi: 10.1056/NEJMoa2007016. PubMed DOI PMC

Heaney JLJ, Campbell JP, Iqbal G, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018;32:1727–1738. doi: 10.1038/s41375-018-0163-4. PubMed DOI PMC

Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from International Myeloma Society data set. Blood. 2020;136:3033–3040. doi: 10.1182/blood.2020008150. PubMed DOI PMC

Sorrig R, Klaussen TW, Salomo M, et al. Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population. Plos One. 2017;12(12):e0188988. doi: 10.1371/journal.pone.0188988. PubMed DOI PMC

Heaney JLJ, Cambell JP, Iqbal G, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018;32:1727–1738. doi: 10.1038/s41375-018-0163-4. PubMed DOI PMC

Kazandian D. Multiple myeloma epidemiology and survival: a unique malignancy. Seminar Oncol. 2016;43:676–681. doi: 10.1053/j.seminoncol.2016.11.004. PubMed DOI PMC

Blinmark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–113. doi: 10.3324/haematol.2014.107714. PubMed DOI PMC

Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) Leukemia. 2020;34:2000–2011. doi: 10.1038/s41375-020-0876-z. PubMed DOI PMC

Teh BW, Harrison SJ, Pellegrini M, et al. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev. 2014;28:75–86. doi: 10.1016/j.blre.2014.01.004. PubMed DOI

Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412–3420. doi: 10.1200/JCO.2005.04.242. PubMed DOI

Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473. doi: 10.1038/sj.leu.2404284. PubMed DOI

Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655. doi: 10.1097/00000421-198212000-00014. PubMed DOI

Vijenthira A, Gorg IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. doi: 10.1182/blood.2020008824. PubMed DOI PMC

Chen M, Zhao Y, Xu C, et al. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol. 2018;97:925–944. doi: 10.1007/s00277-018-3284-y. PubMed DOI

Basler M, Lauer C, Beck U, et al. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183:6145–6150. doi: 10.4049/jimmunol.0901596. PubMed DOI

Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020;13:94. doi: 10.1186/s13045-020-00934-x. PubMed DOI PMC

Cook G, Ashcroft A, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic and anti-cancer therapy. Br J Haematol. 2020;190:e83–e86. doi: 10.1111/bjh.16874. PubMed DOI PMC

Sorrig R, Klausen TW, Salomo M, et al. Risk factors for infections in newly diagnosed multiple myeloma patients: a Danish retrospective nationwide cohort study. Eur J Hematol. 2019;102:182–190. doi: 10.1111/ejh.13190. PubMed DOI

Martinez-Lopez J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103. doi: 10.1038/s41408-020-00372-5. PubMed DOI PMC

Salje H, Tran KC, Lefrancq N, et al. Estimating the burden of SARS-Cov-2 in France. Science. 2020;369:208–211. doi: 10.1126/science.abc3517. PubMed DOI PMC